Multiple myeloma and physical activity.
Exercise
Multiple myeloma
Physical activity
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
07 May 2021
07 May 2021
Historique:
received:
22
03
2021
accepted:
28
04
2021
entrez:
8
5
2021
pubmed:
9
5
2021
medline:
13
5
2021
Statut:
epublish
Résumé
Physical activity has been shown to improve quality of life in cancer patients with some evidence in multiple myeloma. This study aimed to determine myeloma patients' exercise levels, their perception of physical activity, and to explore correlations with quality of life. Myeloma outpatients were invited to complete a number of questionnaires, including the Godin leisure-time exercise questionnaire (GLTEQ) to determine their exercise levels, the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire to assess health related quality of life, and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire to assess fatigue. Of the 65 respondents, 75% would like to increase their exercise level. Weakness, fatigue and pain were the most commonly perceived barriers to physical activity. 59% would like to receive physical activity advice. Only 25% were deemed active based on their GLTEQ scores. Finally, there was a significant positive correlation between the GLTEQ score and the FACT-G score (p < 0.001). Results highlight an unmet exercise need in myeloma patients. Current practice should be reviewed to develop a more holistic care model that incorporates tailored exercise advice or programme.
Identifiants
pubmed: 33962674
doi: 10.1186/s13104-021-05591-y
pii: 10.1186/s13104-021-05591-y
pmc: PMC8103584
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171Subventions
Organisme : Cancer Research UK
ID : 14133
Pays : United Kingdom
Organisme : Department of Health
ID : ICA-CDRF-2017-03-067
Pays : United Kingdom
Organisme : Takeda Pharmaceutical Company
ID : 19045
Organisme : RM Partners, U.K.
ID : 177569
Références
BMC Cancer. 2013 Jul 01;13:319
pubmed: 23815855
Cancer. 2002 Jan 15;94(2):528-38
pubmed: 11900238
Support Care Cancer. 2004 Nov;12(11):780-8
pubmed: 15322968
Transl Behav Med. 2020 Oct 12;10(5):1098-1109
pubmed: 33044541
Cochrane Database Syst Rev. 2012 Nov 14;11:CD006145
pubmed: 23152233
Br J Cancer. 2020 Jul;123(2):187-195
pubmed: 32435057
Clin Adv Hematol Oncol. 2017 Apr;15(4):285-295
pubmed: 28591104
BMJ Open. 2020 Jan 29;10(1):e033176
pubmed: 32001493
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
BMJ Open. 2018 Mar 9;8(3):e021333
pubmed: 29525775
Support Care Cancer. 2005 Apr;13(4):246-54
pubmed: 15549424
J Psychosom Res. 2013 Jan;74(1):64-8
pubmed: 23272990
Health Qual Life Outcomes. 2017 Jun 30;15(1):132
pubmed: 28666465
Support Care Cancer. 2014 Feb;22(2):417-26
pubmed: 24122403
BMC Cancer. 2013 Jan 24;13:31
pubmed: 23347597
Br J Haematol. 2017 Mar;176(6):888-907
pubmed: 28107574
BMJ Support Palliat Care. 2020 Dec;10(4):e35
pubmed: 31253733
Eur J Cancer Care (Engl). 2015 Jul;24(4):522-30
pubmed: 25732397